1. How we choose factor VIII to treat hemophilia
by Pier Mannuccio Mannucci, Maria Elisa Mancuso, and Elena Santagostino
Blood
Volume 119(18):
May 3, 2012
©2012 by American Society of Hematology

2. Cumulative incidence of FVIII inhibitors in previously untreated or minimally treated patients with hemophilia A exposed only to single plasma-derived FVIII products (left panel open bars) or recombinant products (right panel closed bars).
Cumulative incidence of FVIII inhibitors in previously untreated or minimally treated patients with hemophilia A exposed only to single plasma-derived FVIII products (left panel open bars) or recombinant products (right panel closed bars). The data from these studies were the broad basis of the systematic reviews.28,33,34 The names in the horizontal axis are those of the first authors of the corresponding articles, which are cited in the aforementioned systematic reviews.
Pier Mannuccio Mannucci et al. Blood 2012;119:
©2012 by American Society of Hematology